MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Carbylan Therapeutics Company Profile (NASDAQ:CBYL)

Consensus Ratings for Carbylan Therapeutics (NASDAQ:CBYL) (?)
Ratings Breakdown: 2 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $7.95 (1,051.01% upside)

Analysts' Ratings History for Carbylan Therapeutics (NASDAQ:CBYL)
Show:
DateFirmActionRatingPrice TargetActions
4/18/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$9.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016WedbushReiterated RatingOutperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2016Leerink SwannDowngradeOutperform -> Market Perform$15.00 -> $1.80View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015Northland SecuritiesReiterated RatingOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Carbylan Therapeutics (NASDAQ:CBYL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
11/11/2015        
11/11/2015Q315($0.26)($0.19)$0.01 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.21)($0.37)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Carbylan Therapeutics (NASDAQ:CBYL)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.24)($0.23)($0.24)
Q2 20162($0.27)($0.25)($0.26)
Q3 20162($0.29)($0.28)($0.29)
Q4 20161($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)
Dividend History for Carbylan Therapeutics (NASDAQ:CBYL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Carbylan Therapeutics (NASDAQ:CBYL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/30/2015David RenziCEOSell10,000$3.70$37,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2015Acmp Iv LlcMajor ShareholderBuy877,500$5.00$4,387,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2015Albert ChaDirectorBuy1,012,500$5.00$5,062,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Carbylan Therapeutics (NASDAQ:CBYL)
DateHeadline
06/24/16 03:12 PMCarbylan Therapeutics, Inc. (NASDAQ:CBYL) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 03:12 PMPrice Target Update on Carbylan Therapeutics (NASDAQ:CBYL) - Trade Calls
06/24/16 10:55 AMCarbylan Therapeutics, Inc. (CBYL) Updated Price Targets - FTSE News
06/22/16 03:48 PMCARBYLAN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhi -
06/22/16 03:12 PMStrong Buy Calls Count For Carbylan Therapeutics, Inc. (NASDAQ:CBYL) At 2 - Investor Newswire
06/22/16 03:00 PMCarbylan Therapeutics and KalVista Pharmaceuticals Conference Call to Discuss Proposed Transaction - [GlobeNewswire] - SALISBURY, United Kingdom and PALO ALTO, Calif., June 22, 2016-- KalVista Pharmaceuticals Ltd., a privately held biopharmaceutical company, and Carbylan Therapeutics, Inc., today announced conference call ...
06/19/16 02:58 PMCarbylan Therapeutics, Inc. (CBYL) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 02:59 PMStocks inside Analysts Spotlight: ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) , Carbylan Therapeutics, Inc. (NASDAQ ... - Street Updates
06/17/16 05:04 AMCARBYLAN THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/16/16 08:27 PMAnalyst Buzz: Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - News Oracle
06/16/16 03:06 PMCarbylan Therapeutics (CBYL) Enters Merger Agreement with Privately-Held KalVista
06/15/16 07:54 AMWhat should one expect from? - Carbylan Therapeutics, Inc. (NASDAQ:CBYL), Rovi Corporation (NASDAQ:ROVI) - Beacon Chronicle
06/15/16 07:54 AMCarbylan Therapeutics (CBYL) Enters Merger Agreement with Privately-Held KalVista - StreetInsider.com
06/15/16 06:53 AMCARBYLAN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material -
06/15/16 06:39 AMCarbylan Therapeutics, Inc. and KalVista Pharmaceuticals Ltd. Enter into Share Purchase Agreement - [at noodls] - --Transaction forms combined NASDAQ-listed biopharmaceutical company, focused on the discovery, development and commercialization of plasma kallikrein inhibitors for the treatment of hereditary angioedema ...
06/15/16 06:31 AM7:31 am Carbylan Therapeutics and KalVista Pharma enter definitive share purchase agreement pursuant to which KalVista will become the majority owners of co -
06/14/16 03:02 PMValuable Price Trends to Observe: Argos Therapeutics, Inc. (NASDAQ:ARGS) , Carbylan Therapeutics, Inc. (NASDAQ ... - Street Updates
06/14/16 07:23 AMAnalyst Recommended These Stocks for Investors: Carbylan Therapeutics, Inc. (NASDAQ:CBYL), Fairmount Santrol ... - Beacon Chronicle
06/11/16 11:19 AMHave a look at Analyst Actions: Carbylan Therapeutics, Inc. (NASDAQ:CBYL) , BioDelivery Sciences International, Inc ... - Street Updates
06/10/16 03:10 PMTrend Of Rating Given To Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - Investor Newswire
06/09/16 10:32 AMCarbylan Therapeutics, Inc. (NASDAQ:CBYL) Stock Rises, Analysts: Hold Rating - iStreetWire
06/09/16 10:32 AMTwo Buzzers within Investors Radar: Amarin Corporation PLC (NASDAQ:AMRN) , Carbylan Therapeutics, Inc ... - Street Updates
06/08/16 03:35 PMCurrent Update on Price Fluctuations: Carbylan Therapeutics, Inc. (NASDAQ:CBYL) , Northwest Biotherapeutics, Inc ... - Street Updates
06/07/16 04:30 PMETF’s with exposure to Carbylan Therapeutics, Inc. : June 7, 2016 -
06/07/16 03:05 PMAnalytical Report of the Stocks: Carbylan Therapeutics, Inc. (NASDAQ:CBYL), Newfield Exploration Co. (NYSE:NFX) - Beacon Chronicle
06/06/16 02:58 PMGyrodyne, LLC (NASDAQ:GYRO) Went Down -0.06%: Carbylan Therapeutics, Inc. (NASDAQ:CBYL), MarketAxess ... - KC Register
06/06/16 02:58 PMHealthcare Gainers Grab Market Attentions- Lion Biotechnologies (NASDAQ:LBIO), Carbylan Therapeutics (NASDAQ ... - Seneca Globe
06/06/16 02:58 PMWorthy Stock Update: Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - News Oracle
06/06/16 02:58 PMAnalysts Review of Stocks: Carbylan Therapeutics, (CBYL) , GlaxoSmithKline PLC (GSK) - Street Updates
06/06/16 11:13 AMCarbylan Therapeutics, Inc. :CBYL-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/06/16 08:04 AMWhy Investors Have This Drug Makers' Stocks on Their Radar? - Carbylan Therapeutics, Catalent Inc., Medicines Co., and Diplomat Pharmacy
06/04/16 08:27 PMTop Gainers Stocks Alerts: Lion Biotechnologies Inc (NASDAQ:LBIO), Carbylan Therapeutics Inc (NASDAQ:CBYL) - NYSE Journal (press release)
06/03/16 03:11 PMEarnings Review: New Residential Investment Corp. (NYSE:NRZ), Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - Beacon Chronicle
06/03/16 03:11 PMTrending Stock Update: Carbylan Therapeutics Inc (NASDAQ:CBYL) - The Point Review
06/03/16 11:45 AMShare Rating Focus on Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - HNN
06/03/16 11:45 AMHealthcare Trading Stocks: Relypsa, Inc. (NASDAQ:RLYP) , Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - Is stories
06/02/16 09:10 PMNews Sentiment For Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - Investor Newswire - News Sentiment For Carbylan Therapeutics, Inc. (NASDAQ:CBYL)Investor NewswireCarbylan Therapeutics, Inc. (NASDAQ:CBYL) has been given a sentiment score of 0.01 by research firm. Coming to the sentiment scale, the impact score measured on daily basis stands on a 1-100 scale. This score is taken into account to get the ...and more »
06/02/16 11:53 AMTarget Price and Stock Performance Rundown for Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - HNN - Target Price and Stock Performance Rundown for Carbylan Therapeutics, Inc. (NASDAQ:CBYL)HNNDuring the latest trading session, Carbylan Therapeutics, Inc. (NASDAQ:CBYL) shares traded -2.73%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been seen ...and more »
05/31/16 08:05 AMHealthcare Stocks within Traders Concentration: CVS Health Corporation (NYSE:CVS) , Carbylan Therapeutics, Inc ... - Is stories - Is storiesHealthcare Stocks within Traders Concentration: CVS Health Corporation (NYSE:CVS) , Carbylan Therapeutics, Inc ...Is storiesIn most recently trading session on 5/27/2016, Carbylan Therapeutics, Inc. (NASDAQ:CBYL) climbed +8.71% while traded on 964.16 thousand shares versus it's an average volume of 1.16 million shares. The company recorded the last trade with the price of ...and more »
05/27/16 01:38 PMStock Rating Review for Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - Wall Street Hints and News - Stock Rating Review for Carbylan Therapeutics, Inc. (NASDAQ:CBYL)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 2 on shares of Carbylan Therapeutics, Inc. (NASDAQ:CBYL). Covering ...and more »
05/27/16 01:38 PMNoteworthy Analyst's Rating to Observe: Medtronic plc (NYSE:MDT) , Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - Street Updates - Noteworthy Analyst's Rating to Observe: Medtronic plc (NYSE:MDT) , Carbylan Therapeutics, Inc. (NASDAQ:CBYL)Street UpdatesOn 5/26/2016, shares of Medtronic plc (NYSE:MDT) rose +0.12% in trading session and finally closed at $81.18. The company most recent volume stood at 4.01 million shares as compared to average volume of 5.29 million shares. Over the one year trading ...and more »
05/27/16 01:38 PMHold Calls Count For Carbylan Therapeutics, Inc. (NASDAQ:CBYL) At 2 - RealistInvestor.com - Hold Calls Count For Carbylan Therapeutics, Inc. (NASDAQ:CBYL) At 2RealistInvestor.comBuy calls count on Carbylan Therapeutics, Inc. (NASDAQ:CBYL)'s stock stands at 0 while Sell recommendations is 0. Hold recommendation is 2. Carbylan Therapeutics, Inc. (NASDAQ:CBYL) has a total of 2 Strong Buy recommendations and 0 Strong Sell ...Carbylan Therapeutics, Inc. (NASDAQ:CBYL) Tracking Stock Rating and Target ProjectionsThe Postall 556 news articles »
05/26/16 12:42 PMTarget Check and Stock Performance Recap Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - Wall Street Hints and News - Target Check and Stock Performance Recap Carbylan Therapeutics, Inc. (NASDAQ:CBYL)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Carbylan Therapeutics, Inc.and more »
05/26/16 12:42 PMEarnings Report of the Stock: Hewlett Packard Enterprise (HPE), Carbylan Therapeutics (CBYL) - Beacon Chronicle - Beacon ChronicleEarnings Report of the Stock: Hewlett Packard Enterprise (HPE), Carbylan Therapeutics (CBYL)Beacon ChronicleLast Trade: The Company closed its last session at $ 1.10yesterday with the gain of 10.01%. The market capitalization of the company is $ 28.96 Million, with the average Volume of $ 1.84 Million. The stock currently has its 52-Week High range of $ 9.22 ...and more »
05/26/16 12:42 PMTwo Movers within Analysts Observation: Carbylan Therapeutics, Inc. (NASDAQ:CBYL) , Celldex Therapeutics, Inc ... - Street Updates - Two Movers within Analysts Observation: Carbylan Therapeutics, Inc. (NASDAQ:CBYL) , Celldex Therapeutics, Inc ...Street UpdatesCelldex Therapeutics, Inc. (NASDAQ:CLDX) after beginning at $4.23, closed at $4.22 by building up +0.24% in recent trading session. Most recent session's volume of 2.74 million shares lower than its average volume of 4.16 million shares. The company ...and more »
05/19/16 12:04 PMCARBYLAN THERAPEUTICS, INC. Financials -
05/12/16 03:36 PMCARBYLAN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -
04/18/16 03:32 PMCARBYLAN THERAPEUTICS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Director -
04/15/16 09:06 AMCarbyian Therapeutics Suspends Further Clinical Development Of Hydros-TA -
04/15/16 06:47 AMCarbylan Therapeutics Announces Decision to Pursue Strategic Transaction - [at noodls] - PALO ALTO, Calif., April 15, 2016 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company, announced today that it has suspended further clinical development of Hydros-TA ...
About Carbylan Therapeutics

Carbylan Therapeutics logoCarbylan Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of combination therapies. The Company's focus is on the development of Hydros-TA, its intra-articular injectable product candidate to treat pain associated with osteoarthritis (OA) of the knee. The Hydros-TA is a cross-linked combination of low dose corticosteroid and hyaluronic acid viscosupplement, designed to provide OA pain relief through a single intra-articular injection. Its technology includes drug/device combination products under development based on chemically engineered polymer systems incorporating hyaluronic acid, a polysaccharide present in the human body. Hydros-TA utilizes crosslinking technology to deliver both short-term pain relief with a low dose corticosteroid triamcinolone acetonide (TA) and sustained pain relief from its hyaluronic acid viscosupplement. The Company has not generated any revenues.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CBYL
  • CUSIP:
Key Metrics:
  • Previous Close: $0.77
  • 50 Day Moving Average: $0.9485
  • 200 Day Moving Average: $1.3473
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $18.19M
  • Current Quarter EPS Consensus Estimate: $-0.8900 EPS
Additional Links:
Carbylan Therapeutics (NASDAQ:CBYL) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha